What is Lipoprotein Apheresis?
Lipoprotein apheresis (LA) is an extracorporeal blood filtration procedure that removes atherogenic apolipoprotein B-containing lipoproteins—primarily LDL cholesterol and lipoprotein(a)—from the bloodstream, achieving acute reductions of 60-80% in these particles through specialized filtration systems. 1, 2
Mechanism and Technical Aspects
LA works by circulating the patient's blood through specialized columns or filters that selectively bind and remove LDL-C and Lp(a) particles while returning the treated blood to the patient. The procedure typically processes 1-2 plasma volumes (calculated as body weight in kg × 0.045 L) or equivalent blood volumes over 2-4 hours, performed weekly or fortnightly in specialized settings such as lipid clinics, nephrology units, or blood transfusion centers. 1
Vascular Access
- Initial access via peripheral veins is preferred
- Arteriovenous fistula may be required if peripheral access becomes impossible (particularly relevant in children)
- Central venous catheters are reserved for emergencies or temporary measures only 1
Special Consideration for Children
For children weighing <30 kg, plasma exchange requires a smaller extracorporeal blood volume than standard LA and is the recommended alternative 1
Beyond Lipid Lowering: Pleiotropic Effects
While the primary mechanism is mechanical removal of atherogenic lipoproteins, LA exerts multiple additional beneficial effects that contribute to cardiovascular risk reduction: 3, 2, 4
- Reduces proinflammatory and prothrombotic factors
- Decreases blood viscosity and improves rheology
- Increases microvascular myocardial perfusion
- May improve endothelial function
- Alters lipoprotein particle proteomics, including reduction of oxidized-LDL particles
- Reduces circulating inflammatory markers
- Lowers PCSK9 levels
These pleiotropic effects may explain why LA demonstrates clinical benefit beyond what would be predicted from lipid lowering alone 3, 4.
Clinical Indications
Class I (Strongest) Recommendations
Homozygous Familial Hypercholesterolemia (HoFH):
- Children aged ≥3 to <8 years and adults with HoFH who fail to achieve LDL-C goals despite maximally tolerated combination drug therapy 1
- These patients face myocardial infarction risk even in childhood without adequate therapy 5
Heterozygous Familial Hypercholesterolemia (HeFH) with Progressive Disease:
- Adults with phenotypic HeFH and progressive atherosclerotic cardiovascular disease (ASCVD) who do not achieve LDL-C goals despite combined treatment with high-potency statin, ezetimibe, and PCSK9 inhibitor
- Particularly indicated when lipoprotein(a) concentration is ≥125 nmol/L (≥60 mg/dl) 1
Evidence for Elevated Lipoprotein(a)
LA is currently the only available therapy capable of effectively reducing elevated Lp(a) levels, an independent cardiovascular risk factor. 3, 6 German registry data demonstrate approximately 80% reduction in major adverse cardiovascular events (MACE) in patients with Lp(a) >60 mg/dL and controlled LDL-C (~100 mg/dL) on maximal therapy, with MACE rates dropping from 0.41-2.80 per year pre-apheresis to 0.08-0.14 per year post-apheresis 3.
Monitoring and Efficacy Assessment
Efficacy is monitored through:
Acute reductions: Measure immediate post-procedure drops in LDL-C and Lp(a) (target 65-70% reduction) 1
Interval mean calculation using the Kroon formula:
- Cmean = Cmin + k(Cmax – Cmin)
- Where Cmax = pre-procedure value, Cmin = post-procedure value
- k = 0.65 for LDL-C in HoFH patients
- k = 0.71 for LDL-C in HeFH patients on statins with fortnightly apheresis
- k = 0.71 also applies for Lp(a) estimation 1
Disease progression monitoring:
- Annual echocardiography or coronary angiography in patients with aortic root or coronary artery disease 1
Important Management Considerations
Medication Adjustments
ACE inhibitors must be avoided in patients undergoing LA based on apolipoprotein B adsorption; substitute with angiotensin-receptor blockers instead 1
Anticoagulation management:
- Warfarin requires dose adjustment or discontinuation several days before procedures using intravenous heparin
- Direct oral anticoagulants (apixaban, dabigatran, rivaroxaban) need only be stopped on the day of apheresis due to shorter half-life
- Antiplatelet therapy should be maintained 1
Concurrent Pharmacotherapy
All lipid-lowering medications must be continued during LA treatment 1. The procedure is adjunctive, not replacement therapy.
PCSK9 inhibitors (evolocumab or alirocumab) should be attempted in all patients before starting or while receiving LA—these agents are particularly effective in HeFH and may sometimes replace the need for apheresis. Injections should be administered soon after, but not immediately before, an apheresis procedure 1
Monitoring for Complications
- Routine full blood counts: Monitor regularly for iron-deficiency anemia, which may develop with long-term LA
- Iron supplementation: Initiate if anemia develops 1
- Comprehensive psychosocial support should be offered to all patients receiving LA 1
Clinical Outcomes
Multiple observational studies and the German Lipoprotein Apheresis Registry (with >10-year follow-up data) demonstrate strong evidence for improved cardiovascular outcomes with LA, though randomized controlled trials are lacking 3, 7, 5. The absence of RCT data reflects ethical concerns in Germany (where LA is approved for these indications) about randomizing patients to no apheresis when the therapy is already approved 3.
Current Utilization and Future Outlook
LA use varies dramatically by geography: In the United States, fewer than 50 patients with ongoing CVD and isolated elevated Lp(a) receive LA therapy, whereas Germany treats >1,500 such patients 3. This reflects differences in regulatory approval and reimbursement policies rather than differences in evidence.
The future role of LA is evolving: With the development of potent RNA-based Lp(a)-lowering agents (pelacarsen, olpasiran, lepodisiran) in late-stage trials, LA utilization may progressively contract for LDL-centric indications while maintaining a role in Lp(a)-driven disease until these novel agents demonstrate outcome benefit 6, 8, 9.